Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

Figure 1

Kaplan–Meier survival analysis according to tamoxifen treatment and PI3K and/or MAPK pathway marker. (A) Kaplan–Meier survival analysis according to tamoxifen treatment and p-p70S6K expression: recurrence-free interval according to tamoxifen treatment in patients whose tumors do not express p-p70S6K (left) and patients whose tumors do express p-p70S6K (right). (B) Kaplan–Meier survival analysis according to tamoxifen treatment and p-mTOR and p-ERK1/2 expression: recurrence-free interval according to tamoxifen treatment in patients whose tumors do express low p-mTOR and are p-ERK1/2 negative (left) and in patients whose tumors do express p-ERK1/2 and/or express high p-mTOR (right). Contr, control; ERK, extracellular signal-regulated kinase; HR, hazard ratio; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-kinase; p, phosphorylated; TAM, tamoxifen.

Back to article page